RYSTIGGO 140 mg/ml, solution for injection bottle, 2 ml
Active ingredients: ROZANOLIXIZUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 2 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RYSTIGGO 140 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon en verre de 2 mL
- Marketing authorisation holder
- UCB PHARMA BELGIQUE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 6 May 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
68822785CIP73028474CIP133400930284742Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ROZANOLIXIZUMABsolution | 140 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.